Defendant

Hetero Drugs Limited

2 cases as defendant.

Cases
2
Active
0
2 closed
Filed
2019–2020
Top venue
D. New Jersey
1 case

Company profile

Let me verify the litigation context and group structure.

Hetero Drugs Limited ("Hetero")

Company overview. Hetero Drugs Limited is an Indian pharmaceutical manufacturer founded in 1993 by Dr. Bandi Partha Saradhi Reddy and headquartered in Hyderabad, Telangana (Sanathnagar Industrial Estate). It is a public unlisted Indian company — not listed on any exchange — and therefore privately held; SEC filings and exchange tickers do not apply. Indian MCA records list FY2025 revenue above ₹1,000 crore (Tracxn); CARE Ratings reports standalone total operating income of ₹2,926 crore in FY24 (down from ₹3,235 crore in FY23) for Hetero Drugs Limited and rates the group's formulation arm, Hetero Labs Limited, separately. Hetero's own 2019–20 sustainability report cites 13,212 permanent employees; third-party aggregators give higher group-wide estimates (Owler: ~21,000 employees, ~$850M revenue), which I could not confirm from a primary source.

Products / operations. Hetero is an operating, vertically integrated generic-drug company. Its portfolio spans active pharmaceutical ingredients (over 120 API products, with 130+ DMF filings as of September 2024), finished dosages/generics, biosimilars, and custom pharmaceutical services. It describes itself as the world's largest producer of anti-retroviral drugs and supplies APIs to Indian, US, and European generic and branded manufacturers. Therapeutic coverage includes HIV/AIDS, oncology, cardiovascular, CNS, hepatitis, and diabetes. The group operates numerous manufacturing facilities approved by global regulators.

Litigation posture. Hetero appears exclusively as a defendant — 2 tracked cases, 0 as plaintiff — consistent with an operating company defending Hatch-Waxman/ANDA patent suits rather than asserting patents. Both cases are Celgene Corporation v. Hetero Labs Limited et al. in the U.S. District Court for the District of New Jersey, not a plaintiff-friendly NPE venue.

Notable cases. The tracked suits involve Celgene's lenalidomide (Revlimid) patents; the October 2020 action followed Hetero's ANDA No. 212414 filing. A September 2021 consent judgment restricted Hetero's generic Revlimid entry. Hetero's Celgene settlements were later referenced in follow-on antitrust litigation (MSP Recovery, Cigna, Humana) alleging reverse payments, though the court found those allegations insufficiently pleaded as to Hetero specifically.

Celgene Corporation v. Hetero Labs Limited et al.

consent judgment
Docket:
2:20-cv-14389
Filed:
2020-10-13
Terminated:
2021-09-27
Patents:8648095

Celgene sued Hetero entities for ANDA patent infringement in D.N.J. This follow-on to Celgene v. Hetero (2:18-cv-17463) is linked to 8,648,095; consent judgment entered 2021-09-27 with marketing injunction and confidential terms.

Celgene Corporation v. Hetero Labs Limited et al.

consolidated; terminated
Docket:
2:19-cv-05797
Filed:
2019-02-14
Terminated:
2020-10-28

Hatch-Waxman ANDA infringement action filed by Celgene against Hetero entities; the complaint expressly asserts the '647, '648, and '649 patents. Consolidated with related 2019 cases before Judge Esther Salas / M.J. Michael A. Hammer and docket shows termination Oct. 28, 2020.